Literature DB >> 21881813

Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?

Thyciara Fontenele Marques1, Renata Vasconcelos, Erik Diniz, Daniela Rêgo, Luiz Griz, Francisco Bandeira.   

Abstract

OBJECTIVE: To describe the characteristics of normocalcemic primary hyperparathyroidism (NPHPT) in patients seen for osteoporosis evaluation. PATIENTS AND METHODS: We examined the records of 156 women who came to the hospital to be screened for osteoporosis. Measurements of total calcium, PTH, 25-hydroxy vitamin D, and β-C-telopeptide were recorded. Bone mineral density and T-scores were evaluated by densitometry of the lumbar spine, femoral neck and distal one-third of the radius. The latter was only measured in patients with primary hyperparathyroidism. Nephrolithiasis and bone fractures were documented by a review of the medical records.
RESULTS: We identified 14 patients with NPHPT, accounting for 8.9% of the population studied. In the medical records, the occurrence of kidney stones was reported in 28.6% of the patients with NPHPT, in contrast with only 0.7% of the noncarriers. Regarding the presence of general fractures, 21.4% of the patients with NPHPT were affected versus 16.2% of noncarriers.
CONCLUSION: Data from our study suggest that NPHPT has a diverse phenotypic presentation, implying that this may not be an "indolent" disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881813      PMCID: PMC4357231          DOI: 10.1590/s0004-27302011000500003

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  12 in total

Review 1.  Asymptomatic primary hyperparathyroidism: new issues and new questions--bridging the past with the future.

Authors:  John P Bilezikian; John T Potts
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

2.  Serum ionized calcium and parathyroid hormone in renal stone disease.

Authors:  F P Muldowney; R Freaney; J P McMullin; R P Towers; A Spillane; P O'Connor; P O'Donohoe; M Moloney
Journal:  Q J Med       Date:  1976-01

3.  Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention.

Authors:  A M Parfitt; D S Rao; M Kleerekoper
Journal:  J Bone Miner Res       Date:  1991-10       Impact factor: 6.741

4.  Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course.

Authors:  D S Rao; R J Wilson; M Kleerekoper; A M Parfitt
Journal:  J Clin Endocrinol Metab       Date:  1988-12       Impact factor: 5.958

5.  A comparative study of serum ultrafiltrable, ionized, and total calcium in the diagnosis of primary hyperparathyroidism in patients with intermittent or no elevation in total calcium.

Authors:  J Forster; J M Monchik; H F Martin
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

6.  Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women.

Authors:  E Lundgren; J Rastad; E Thrufjell; G Akerström; S Ljunghall
Journal:  Surgery       Date:  1997-03       Impact factor: 3.982

7.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.

Authors:  S J Silverberg; E Shane; T P Jacobs; E Siris; J P Bilezikian
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

8.  "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease.

Authors:  Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

9.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.

Authors:  H Lowe; D J McMahon; M R Rubin; J P Bilezikian; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

Review 10.  Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors:  Shonni J Silverberg; E Michael Lewiecki; Leif Mosekilde; Munro Peacock; Mishaela R Rubin
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

View more
  15 in total

Review 1.  Mild primary hyperparathyroidism: a literature review.

Authors:  Megan K Applewhite; David F Schneider
Journal:  Oncologist       Date:  2014-07-25

Review 2.  Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm.

Authors:  Joaquín Gómez-Ramírez; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2017-08-19       Impact factor: 3.445

3.  Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.

Authors:  Emma O Billington; Greg D Gamble; Ian R Reid
Journal:  Bonekey Rep       Date:  2016-12-07

Review 4.  Current opinions on nephrolithiasis associated with primary hyperparathyroidism.

Authors:  Xiaoming Cong; Luming Shen; Xiaojian Gu
Journal:  Urolithiasis       Date:  2018-01-19       Impact factor: 3.436

5.  Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia.

Authors:  Manabu Okada; Yoshihiro Tominaga; Tetsuhiko Sato; Toshihide Tomosugi; Kenta Futamura; Takahisa Hiramitsu; Toshihiro Ichimori; Norihiko Goto; Shunji Narumi; Takaaki Kobayashi; Kazuharu Uchida; Yoshihiko Watarai
Journal:  BMC Nephrol       Date:  2022-06-17       Impact factor: 2.585

6.  Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?

Authors:  Emanuela Traini; Rocco Bellantone; Serena Elisa Tempera; Salvatore Russo; Carmela De Crea; Celestino Pio Lombardi; Marco Raffaelli
Journal:  Langenbecks Arch Surg       Date:  2018-03-14       Impact factor: 3.445

7.  Reduced parathyroid hormone-stimulated 1,25-dihydroxyvitamin d production in vitamin d sufficient postmenoposual women with low bone mass and idiopathic secondary hyperparathyroidism.

Authors:  Elizabeth A Streeten; Amy S Rogstad; Kristin M Flammer; Kiarash Zarbalian; Kathleen Ryan; Mara Horwitz; Michael F Holick; John Shelton
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

8.  Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More Stone than Bone?

Authors:  L M Amaral; D C Queiroz; T F Marques; M Mendes; F Bandeira
Journal:  J Osteoporos       Date:  2012-03-25

Review 9.  Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.

Authors:  A A Khan; D A Hanley; R Rizzoli; J Bollerslev; J E M Young; L Rejnmark; R Thakker; P D'Amour; T Paul; S Van Uum; M Zakaria Shrayyef; D Goltzman; S Kaiser; N E Cusano; R Bouillon; L Mosekilde; A W Kung; S D Rao; S K Bhadada; B L Clarke; J Liu; Q Duh; E Michael Lewiecki; F Bandeira; R Eastell; C Marcocci; S J Silverberg; R Udelsman; K Shawn Davison; J T Potts; M L Brandi; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-09-09       Impact factor: 4.507

Review 10.  Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach.

Authors:  Guido Zavatta; Bart L Clarke
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.